Yahoo Italia Ricerca nel Web

Entra

Risultati di ricerca

  1. stockanalysis.com › stocks › vndaVanda Pharmaceuticals Inc. (VNDA) - Stock Analysis

    4 giorni fa · Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results. Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder... 11 days ago - PRNewsWire.

    • 246.26M
    • 192.64M
    • 2.51M
    • 57.54M

  2. simplywall.st › nasdaq-vnda › vanda-pharmaceuticalsVanda Pharmaceuticals NasdaqGM:VNDA Stock Report - Simply Wall St

    2 giorni fa · VNDA Stock Overview. A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. About the company. Rewards. Trading at 96.6% below our estimate of its fair value. Trading at good value compared to peers and industry. Risk Analysis.

  3. seekingalpha.com › news › 4110407-vanda-pharmaceuticalsVanda Pharmaceuticals rejects sweetened bid from Future Pak

    2 ore fa · Vanda Pharmaceuticals (NASDAQ:VNDA) rejected a sweetened takeover offer from Future Pak. Vanda (VNDA) said the offer for $7.25 to $7.75 per share in cash plus certain contingent value rights ...

  4. www.marketbeat.com › stocks › NASDAQVanda Pharmaceuticals (VNDA) Stock Price, News & Analysis -...

    2 giorni fa · Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

    • (202) 734-3400
    • 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037
    • pr@vandapharma.com

  5. it.marketscreener.com › quotazioni › azioneVanda Pharmaceuticals rifiuta l'accordo di Future Pak

    23 ore fa · Vanda Pharmaceuticals rifiuta la proposta di acquisizione di Future Pak. 17/04. RE. Future Pak, Ltd. ha annullato l'acquisizione di Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) da The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP e altri. 17/04.

  6. Immagini

    • TD Asset Management Inc. Takes $262,000 Position in Vanda ...
    • Vanda Pharmaceuticals to raise at least $54M in stock offering ...
    • Home | Vanda Ario Energy

    Mostra tutto

  7. in.marketscreener.com › quote › stockVanda Pharmaceuticals Board of Directors Determines that Revised...

    3 ore fa · WASHINGTON, May 24, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. today announced that the Company's Board of Directors carefully reviewed the revised unsolicited proposal from Future Pak, LLC ...

  8. www.marketscreener.com › quote › stockVanda Pharmaceuticals rejects Future Pak's deal - MarketScreener

    15 ore fa · May 24 (Reuters) - Vanda Pharmaceuticals said on Friday its board of directors has rejected Future Pak's unsolicited takeover proposal. (Reporting by Sneha S K in Bengaluru; Editing by Arun Koyyur)

  1. Ricerche correlate a "vanda pharm"

    libero quotidiano